Precision radiation medicine company Elekta AB (STO:EKTAB.ST) announced on Monday the signing of a contract with the Institut Jules Bordet, Brussels, for an Elekta Unity MR-linac system, two Versa HD linear accelerators (linacs) and an upgrade of existing Elekta Infinity linacs, as well as upgrades and expansions of Monaco treatment planning software and MOSAIQ oncology information systems and service.
This contract has a total valued of approximately EUR22m, of which EUR18m will be booked in the third quarter of Elekta's fiscal year 2019/20. The remainder will be booked successively over the next 10 years. Elekta won the contract through a public procurement procedure.
Reportedly, this comprehensive cancer centre is gearing up for its new cancer clinic with an investment in state-of-the-art technology and upgrades to existing devices. This includes Elekta Unity, a transformative magnetic resonance radiation therapy (MR/RT) system, which combines a high-field MRI scanner with a best-in-class linear accelerator to enable personalised precision radiation therapy.
The institute already employs Elekta solutions, including Leksell Gamma Knife Icon and two Elekta Infinity linacs, as well as MOSAIQ and Monaco and Elekta's microSelectron brachytherapy afterloading platform. The two Versa HD systems in this contract will replace competing systems.
Upon full deployment of all the solutions, the Jules Bordet Institute is expected to become Belgium's largest single radiation therapy site with four Elekta linacs, one Unity MR-Linac and one Leksell Gamma Knife.
According to Elekta, software upgrades are scheduled for delivery during 2020 and the linear accelerators, including Unity, in 2021.
Elekta, a provider of precision radiation medicine, offers cancer patients more precise, personalized radiotherapy treatments.
Circio unveils circVec proof-of-concept
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients